A strategic approach to COVID-19 vaccine R&D A strategic approach to COVID-19 vaccine R&D By Lawrence Corey 1, 2, John R. Mascola 3, Anthony S. Fauci 4, Francis S. Collins 5 1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 2 Departments of Medicine and Lab Medicine, University of Washington, Seattle, WA 98195, USA. 3 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. 4 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. 5 National Institutes of Health, Bethesda, MD 20892, USA. Email: afauci@niaid.nih.gov This is clearly Fauxi's show and the bottom line is not a surprise: To return to a semblance of previous normality, the development of SARS-CoV-2 vaccines is an absolute necessity. To achieve this goal, all the resources in the public, private, and philanthropic sectors need to participate in a strategic manner. The ACTIV public-private partnership and collaborative harmonized efficacy trials are enabling models to achieve our common goal.